---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-018808"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:55:59.626178+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q1 revenue record $18.5M; CEO Fleming resigns, Chairman Nixon takes over

## Summary
- Net revenue $18.5M in Q1 2024, up 19% YoY; tenth consecutive record quarter.
- Net loss $1.8M vs $1.2M loss in prior year; Adjusted EBITDA turned positive at $0.3M.
- CEO Zachary Fleming resigned May 10, 2024; Board appointed Executive Chairman Ron Nixon as new CEO effective immediately.
- Subsequent to quarter end, entered $55M non-dilutive term loan with CRG; received $15M at closing with option for additional $40M.
- Appointed Jake Waldrop as COO and Tyler Palmer as Chief Corporate Development and Strategy Officer.

## SEC filing metadata
- accession: 0001493152-24-018808
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315224018808/0001493152-24-018808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315224018808/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-018808
- JSON: https://secwatch.observer/filing/0001493152-24-018808.json
- Plain text: https://secwatch.observer/filing/0001493152-24-018808.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the quarter ended March 31, 2024 results: revenue $18.5 million, net income net loss of $1.8 million.
  - Period: the quarter ended March 31, 2024
  - Revenue: $18.5 million
  - Net income: net loss of $1.8 million
  - Result: reported results
  source text: resources as well as add to the executive team.” Strategic and Operational Highlights in the First Quarter 2024 ● In the first quarter of 2024, the Company generated a record $18.5 million in sales, representing a tenth consecutive record revenue quarter for the Company. ● For the three months ended March 31, 2024, the Company had a net loss of $1.8 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315224018808/0001493152-24-018808-index.htm
- Executive change
  Ronald T. Nixon was appointed as Chief Executive Officer at Sanara MedTech Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On May 12, 2024, the Board appointed Ronald T. Nixon, the Company’s Executive Chairman, as the Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315224018808/0001493152-24-018808-index.htm
- Executive change
  Zachary B. Fleming departed as Chief Executive Officer at Sanara MedTech Inc..
  - Action: resigning
  - Role: Chief Executive Officer
  source text: On May 10, 2024 (the “Effective Date”), Zachary B. Fleming delivered notice to the Board of Directors of the Company (the “Board”) that he is resigning from his position as Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315224018808/0001493152-24-018808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.